Illumina (ILMN) to Release Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 13th. Analysts expect Illumina to post earnings of $0.92 per share and revenue of $1.08 billion for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm posted $0.33 earnings per share. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, analysts expect Illumina to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Illumina Stock Performance

Shares of ILMN opened at $124.68 on Thursday. The company has a market cap of $19.77 billion, a PE ratio of -12.52 and a beta of 1.10. The firm has a 50-day moving average of $138.19 and a 200-day moving average of $135.50. Illumina has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. Barclays reduced their price target on Illumina from $145.00 to $130.00 and set an “equal weight” rating for the company in a report on Monday. Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Robert W. Baird raised their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Royal Bank of Canada lifted their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, UBS Group increased their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.